PolygenicBlog: Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Provide Broad Coverage Against Deadly Disease
Links shared publicly online about this topic.
- 875total visits
PolygenicBlog: Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Provide Broad Coverage Against Deadly Disease
polygenicpathways.blogspot.com —
View full resource at polygenicpathways.blogspot.com
Tags: Vaccination, Disease and Condition, Genes, Relationship, Vaccine, Novartis, disease
Most Recently Shared on September 14, 2010 at 12:16 am By:
Novartis Phase III Study Shows Meningococcal B Vaccine Candidate Could Be First To Provide… http://goo.gl/fb/4qit5
Novartis International AG (CH) - Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease - Drugs.com MedNews
drugs.com — “Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease Pivotal data show that the larg” View full resource at drugs.com
Most Recently Shared on September 13, 2010 at 1:11 pm By:
Drugs and Devices OW OW Health
Novartis International AG (CH) - Novartis Phase III study shows meningococcal B vaccine candidate could be fi... http://bit.ly/dsxVa3 #drug
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
novartis.com — “Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease” View full resource at novartis.com
Most Recently Shared on September 13, 2010 at 6:30 am By:
Pivotal Ph III data show #Novartis MenB vaccine could be 1st to provide broad coverage against deadly disease http://bit.ly/bmeqZN
Advertisement
